华润医药(03320.HK)旗下两药品获药品补充申请批准通知书

阿斯达克财经
13 May

华润医药(03320.HK) 宣布,旗下安徽双鹤、双鹤天安分别收到国家药品监督管理局颁发的甘油果糖氯化钠注射液和二甲双胍恩格列净片(I)《药品补充申请批准通知书》,并视同通过一致性评价。
甘油果糖氯化钠注射液是一种脱水药,主要用于脑血管病、脑外伤、脑肿瘤、颅内炎症及其他原因引起的急慢性颅内压增高,脑水肿等症。

二甲双胍恩格列净片(I)配合饮食控制和运动,适用于正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者,用于改善这些患者的血糖控制。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-12 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10